EUCTR2006-006638-16-IT进行中（未招募）不适用
A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 and IV bortezomib in adult patients with multiple myeloma - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients must have a diagnosis of active multiple myeloma according to the International Myeloma Working Group criteria (IMWG et.al., 2003), and be deemed by the investigator as requiring treatment. 2. Patients must have received at least one prior line of therapy and their disease has relapsed (Durie et. al., 2006). One prior line of therapy may consist of induction followed by autologous stem cell transplantation. 3. Patients must be suitable (according to their local product information) for treatment with bortezomib. Note: patients previously treated with bortezomib are eligible to participate in the trial. 4. Adults ≥ 18 years old 5. ECOG Performance Status ≤ 2 6. Life expectancy > 12 weeks 7. Patients must have the following laboratory values: ANC ≥ 1.5 x 109/L Hemoglobin ≥ 9 g/dl Platelets ≥ 100x 109/L Calculated CrCl ≥ 50 mL/min (MDRD Formula) AST and ALT ≤ 2.5 x ULN Serum bilirubin ≤ 1.5 x ULN Albumin > 3.0 g/dl Serum potassium ≥ LLN Total serum calcium [corrected for serum albumin] or ionized calcium ≥LLN, Serum magnesium ≥ LLN Serum phosphorus ≥ LLN TSH ≤ LLN and free T4 within normal limits. Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism. Baseline MUGA or ECHO must demonstrate LVEF ≥ the lower limit of the institutional normal Patients participating in the dose-expansion phase of the trial must be willing and able to undergo bone marrow aspirates as per protocol, with/without bone marrow biopsy according to their center?s practice Able to sign informed consent and to comply with the protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Prior exposure to a HDAC inhibitor compound used in the treatment of MM 2. Primary refractory MM 3. Patients who have received allogeneic stem cell transplantation < 12 months prior to entering the study 4. Patients who have had prior allogeneic stem cell transplantation and show evidence of active graft-versus-host disease that requires immunosuppressive therapy 5. Peripheral neuropathy ≥ CTCAE grade 1 6. Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: Patients with congenital long QT syndrome History or presence of sustained ventricular tachyarrhythmia. (Patients with a history of atrial arrhythmia are eligible but should be discussed with the Sponsor prior to enrollment) Any history of ventricular fibrillation or torsade de pointes Bradycardia defined as HR< 50 bpm. Patients with pacemakers are eligible if HR ≥ 50 bpm. Screening ECG with a QTc > 450 msec Right bundle branch block + left anterior hemiblock (bifascicular block) Patients with myocardial infarction or unstable angina ≤ 6 months prior to starting study drug Other clinically significant heart disease (e.g., CHF NY Heart Association class III or IV , uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen) 7. Impairment of GI function or GI disease that may significantly alter the absorption of LBH589 8. Patients with diarrhea > CTCAE grade 1 9. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes or active or uncontrolled infection) including abnormal laboratory values, that could cause unacceptable safety risks or compromise compliance with the protocol 10. Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug 11. Concomitant use of CYP3A4 inhibitors 12. Patients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (which ever is longer) and who have not recovered from side effects of those therapies. 13. Patients who have received either immunotherapy within < 8 weeks; chemotherapy within < 4 weeks; or radiation therapy to > 30% of marrowbearing bone within < 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies. 14. Patients with an active bleeding tendency or is receiving any treatment with therapeutic doses of sodium warfarin (Coumadin) or coumadin derivatives. Low doses of Coumadin (e.g. ≤ 2 mg/day) to maintain line patency (if applicable) is allowed. 15. Patients who have received steroids (e.g. dexamethasone) ≤ 2 weeks prior to starting study treatment or who have not recovered from side effects of such therapy. Concomitant therapy medications that include corticosteroids are allowed if patients receive < 10 mg of prednisone or equivalent as indicated for other medical conditions, or up to 100 mg of hydrocortisone as pre-medication for administration of certain medications or blood products while enrolled in this study. 16. Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy 17. Women who are pregnant or breast feeding or women of childbearing po
研究者
相似试验
进行中（未招募）
不适用
A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 when administered in combination with oral lenalidomide & dexamethasone in adult patients with multiple myelomaMedDRA version: 14.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple MyelomaEUCTR2006-007030-35-ITOVARTIS FARMA40
已完成
不适用
A phase Ib, multi-center, open-label, dose-escalation study of PIM447 in combination with ruxolitinib (INC424) and LEE011 administered orally in patients with myelofibrosis (CPIM447X2104C)10018849myelofibrosisNL-OMON44750ovartis4
已完成
不适用
A phase Ib, open-label, multi-center, dose escalation and expansion study of an orally administered combination of BKM120 plus MEK162 in adult patients with selected advanced solid tumorsSolid tumors10027655cancerNL-OMON43645Array BioPharma Inc.10
招募中
1 期
This study aims to find the best dose of BI 907828 in patients with different types of advanced cancer (solid tumors)Advanced or metastatic solid tumorsJPRN-jRCT2080223999Boehringer Ingelheim200
招募中
1 期
Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHon-Hodgiking LymphomaJPRN-jRCT2031210238Suzuki Kazuyuki86